Tests umbilical cord stem cells in people with hepatitis B liver cirrhosis
Tests donor umbilical cord stem cells in adults with liver scarring caused by hepatitis B.
Key facts
- Who runs it
- PT. Prodia Stem Cell Indonesia
- Where
- Jakarta, IndonesiaSee the site
- Trial code
- Registry title
- Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
- Status
- Enrolling by invitation
- Phase
- Phase 1/2
- People taking part
- 12 people, planned
- Started
- 17 May 2018
- Expected to end
- 20 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Allogeneic Umbilical Cord Mesenchymal Stem Cell
- Record updated
- 25 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with decompensated liver cirrhosis (Child-Pugh B) caused by hepatitis B. It tests stem cell therapy made from umbilical cord cells.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Decompensated liver cirrhosis (Child-Pugh B) caused by hepatitis B infection. Cirrhosis is shown by an ultrasound scan.
- Earlier treatment
- People must be taking hepatitis B drugs for their chronic hepatitis B infection. People who have had a transplant or other stem cell therapy cannot join.
Main reasons for not taking part
- Any cancer, in the liver or elsewhere
- Other infections such as hepatitis C or HIV
- Pregnant or breastfeeding women
- Diabetes, severe heart disease, kidney disease or lung disease
- Alcohol dependence or NASH
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients with decompensated cirrhosis (Child-Pugh B) caused by hepatitis B infection (Cirrhosis is evidenced by the results of ultrasonography examination and chronic hepatitis B infection is found in patients who are taking hepatitis B drugs)
Who cannot take part
- Patients who have undergone transplantation and other stem cell therapy
- Having malignancies disease, both liver malignancies or other malignancies
- Having another co-infections such as hepatitis C and Human Immunodeficiency Virus (HIV)
- Having complications disease such as diabetes mellitus, severe heart disease, kidney disease, and respiratory disease
- Patients who refuse to participate in research
- Pregnant or lactation patients as evidenced by positive pregnancy test results
- Having the case of alcohol dependence and NASH
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Indonesia
- Cipto Mangunkusumo hospitalJakarta, IndonesiaNo longer taking part
About the trial
What the trial wants to find out
The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.
The group in the trial
- intravenous injection of UC-MSCTreatment being tested
The dosage of the intravenous route is 100 million MSCs for each subject.
Treatment: Allogeneic Umbilical Cord Mesenchymal Stem Cell
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B: Phase I/ II Study
- Plain-language title
- Tests umbilical cord stem cells in people with hepatitis B liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04357600, who can take part
- Record updated
- 25 February 2026